SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer
Alterations in SMAD4 were predictive of treatment failure for patients receiving neoadjuvant FFX. These data warrant prospective evaluation and support future trial designs incorporating SMAD4 as a predictive genomic biomarker.
Authors
- Jashodeep Datta (ORCID: https://orcid.org/0000-0003-2869-1571)
- Daniel P. Nussbaum (ORCID: https://orcid.org/0000-0003-3070-6605)
- Nipun B. Merchant (ORCID: https://orcid.org/0000-0002-3399-9776)
- Unaiza Zaman
- Julia Button
- Michael E. Lidsky (ORCID: https://orcid.org/0000-0003-0500-2016)
- Caitlin A. Hester (ORCID: https://orcid.org/0000-0002-3302-0839)
- Susanna Varkey Ulahannan (ORCID: https://orcid.org/0000-0002-7234-2283)
- Elishama Kanu (ORCID: https://orcid.org/0000-0003-4959-9993)
- Brett L. Ecker (ORCID: https://orcid.org/0000-0003-2536-9261)
- David G. Brauer (ORCID: https://orcid.org/0000-0002-0251-4350)
- Emil Lou (ORCID: https://orcid.org/0000-0002-1607-1386)
- Akshat Sarkari (ORCID: https://orcid.org/0000-0002-6890-9021)
- Erin M. Dickey
- Ethan Agritelley (ORCID: https://orcid.org/0009-0009-2728-0552)
- Brian Diskin (ORCID: https://orcid.org/0000-0003-4954-794X)
- Annie Kim (ORCID: https://orcid.org/0000-0001-8100-5492)
- Brock Hewitt
- Vanessa Marin-Guerra
- Rajalaxmi Sharanappa
Institutions
- Saint Barnabas Medical Center (US)
- University of Minnesota (US)
- University of Miami (US)
- Duke University (US)
- Environmental and Occupational Health Sciences Institute (US)
- Oklahoma State University Oklahoma City (US)
- University of Oklahoma Health Sciences Center (US)
- New York University (US)
Publication Details
- Journal
- Annals of Surgery
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1097/sla.0000000000006966
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00